Effect of "Xiaokebizu Bath Prescription" combined with cilostazole in the treatment of diabetic peripheral neuropathy

Objective To observe the clinical effect of Xiaokebizu Bath Prescription combined with cilostazole on diabetic peripheral neuropathy(DPN) and the effect on motor nerve conduction velocity. Methods A total of 112 patients with DPN admitted to our hospital from January 2017 to March 2019 were selected and divided into cilostazol group(56 cases) and combination group(56 cases) according to the different treatment methods. Both groups were given routine basic intervention and cilostazol treatment. The combined group was treated with Xiaokebizu Bath Prescription. Both groups were treated for 8 weeks. The therapeutic effects and adverse reactions of the two groups were observed. Toronto Clinical Score Scale(TCSS) was used to evaluate the severity of symptoms before and after treatment. The motor nerve conduction velocity(MNCV) and sensory nerve conduction velocity(SNCV) of median nerve and common peroneal nerve were compared between the two groups before and after treatment. Results The TCSs score of the combined group was significantly lower than that of the cilostazol group [(4.95±1.37) scores vs.(6.38±2.02) scores]. The MNCV [(50.97±4.28) m/s vs.(47.43±14.15) m/s] and SNCV [(46.05±14.24) m/s vs.(50.44±15.27) m/s] of the median peroneal nerves, the MNCV [(45.27±14.11) m/s vs.(42.34±13.93) m/s] and SNCV [(39.92±15.17) m/s vs.(43.02±15.62) m/s] of the nervus peroneus communis and total effective rate(94.64% vs. 73.21%) in the combined group were significantly higher than those in the cilostazol group(all P<0.05). Conclusion Xiaokebizu Bath Prescription combined with cilostazol can effectively alleviate the clinical symptoms of DPN patients and improve the conduction velocity of diseased nerves. The clinical effect is remarkable and the safety is good.